| Code | CSB-RA008646MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to vofatamab, targeting fibroblast growth factor receptor 3 (FGFR3). FGFR3 is a receptor tyrosine kinase that plays a critical role in cell proliferation, differentiation, and angiogenesis through binding to fibroblast growth factors. Aberrant FGFR3 signaling, including activating mutations and chromosomal translocations, has been implicated in various malignancies, most notably urothelial carcinoma, multiple myeloma, and certain skeletal dysplasias. Dysregulated FGFR3 activity drives oncogenic transformation and tumor progression, making it an important therapeutic target in precision oncology.
Vofatamab is a fully humanized IgG1 monoclonal antibody that specifically binds to FGFR3, blocking ligand binding and receptor activation. This biosimilar antibody provides researchers with a valuable tool for investigating FGFR3-mediated signaling pathways, studying tumor biology in FGFR3-driven cancers, and exploring potential therapeutic mechanisms in preclinical models. It supports research in oncology, cell signaling, and targeted therapy development.
There are currently no reviews for this product.